IOVA
Iovance Biotherapeutics, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Strong buy
+75/100
Last price
12.97
▼ 1.18 (8.34%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
14.09
Prev close
14.15
Day high
14.21
Day low
12.92
Volume
18.93M
Market cap
$5.87B
P/E (TTM)
—
52W range
1.76 – 15.30
Day trading desk
Gap from prior close
-0.40%
Prior close 14.15
VWAP
13.12
-1.12% from price
Relative volume
2.03×
Unusually busy
Session range
11.92%
12.92 – 14.46
Position in range
3%
Near session low
ATR (14D)
1.02
7.83% of price
Prior day high
14.41
PDH
Prior day low
13.71
PDL
Bid / ask spread
—
Quote not published
Session volume
36.08M
Avg 17.73M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-10.31%
-12.3%
1M
+47.44%
+46.3%
3M
+202.80%
+198.3%
6M
+290.36%
+272.2%
YTD
+374.73%
+360.5%
1Y
+453.85%
+437.4%
3Y
+184.84%
+102.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on IOVA open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
1.60M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 8, 26 | BILINSKY IGOR P Chief Operating Officer |
— | 7.81K | — | Direct |
| Sep 8, 26 | VOGT FREDERICK G Chief Executive Officer |
— | 15.63K | — | Direct |
| Sep 8, 26 | PURI RAJ K Officer |
— | 9.77K | — | Direct |
| Sep 1, 26 | BILINSKY IGOR P Chief Operating Officer |
— | 8.79K | — | Direct |
| Sep 1, 26 | VOGT FREDERICK G Chief Executive Officer |
— | 41.67K | — | Direct |
| Sep 1, 26 | PURI RAJ K Officer |
— | 5.47K | — | Direct |
| Aug 10, 26 | KIRBY DANIEL GORDON Officer |
— | 10.00K | — | Direct |
| Aug 6, 26 | ROCHE CORLEEN M Chief Financial Officer |
— | 49.99K | — | Direct |
| Jun 5, 26 | BILINSKY IGOR P Chief Operating Officer |
— | 7.81K | — | Direct |
| Jun 5, 26 | VOGT FREDERICK G Chief Executive Officer |
— | 15.63K | — | Direct |
| Jun 5, 26 | GRAF FINCKENSTEIN FRIEDRICH Officer |
— | 7.81K | — | Direct |
| Jun 5, 26 | PURI RAJ K Officer |
— | 9.77K | — | Direct |
| Jun 1, 26 | BILINSKY IGOR P Chief Operating Officer |
— | 8.79K | — | Direct |
| Jun 1, 26 | VOGT FREDERICK G Chief Executive Officer |
— | 41.67K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BELLEMIN JEAN-MARC |
Chief Financial Officer | 60.53K | Conversion of Exercise of derivative security |
BILINSKY IGOR P |
Chief Operating Officer | 142.07K | Conversion of Exercise of derivative security |
GRAF FINCKENSTEIN FRIEDRICH |
Officer | 140.11K | Conversion of Exercise of derivative security |
KIRBY DANIEL GORDON |
Officer | 154.51K | Conversion of Exercise of derivative security |
MAYNARD RYAN D |
Director | 7.50K | Sale |
PURI RAJ K |
Officer | 256.36K | Conversion of Exercise of derivative security |
ROCHE CORLEEN M |
Chief Financial Officer | 28.76K | Conversion of Exercise of derivative security |
VOGT FREDERICK G |
Chief Executive Officer | 595.45K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$5.87B
Enterprise value$5.62B
Revenue (TTM)$324.97M
Gross profit$157.29M
EBITDA$-259.60M
Net income$-289.52M
EPS (TTM)$-0.63
Free cash flow$-187.79M
Total cash$297.67M
Total debt$46.00M
Book value / share$1.63
Shares outstanding452.97M
Float394.31M
Short % of float20.57%
Dividend yield0.00%
Beta (5Y)0.76
Valuation & profitability ratios
Trailing P/E—
Forward P/E-54.68
PEG ratio—
Price / sales—
Price / book7.98
EV / revenue17.29
EV / EBITDA-21.64
Gross margin48.40%
Operating margin-52.26%
Profit margin-89.09%
Return on equity-40.36%
Return on assets-20.31%
Debt / equity6.25
Current ratio4.35
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $263.50M | $164.07M | $1.19M | $0 | +60.6% |
| Operating revenue | $268.00M | $169.17M | $1.19M | $0 | +58.4% |
| Cost of revenue | $173.18M | $93.25M | $1.03M | $0 | +85.7% |
| Gross profit | $90.32M | $70.82M | $156.00K | $0 | +27.5% |
| Research & development | $300.27M | $276.23M | $333.19M | $294.78M | +8.7% |
| Selling, general & admin | $152.32M | $152.27M | $106.10M | $104.10M | +0.0% |
| Total operating expense | $488.53M | $466.10M | $460.71M | $398.88M | +4.8% |
| Operating income | -$398.21M | -$395.28M | -$460.56M | -$398.88M | -0.7% |
| Net interest income | $10.31M | $20.27M | $13.04M | $2.98M | -49.2% |
| Pre-tax income | -$393.05M | -$375.00M | -$447.52M | -$395.89M | -4.8% |
| Tax provision | -$2.07M | -$2.83M | -$3.48M | $0 | +26.8% |
| Net income | -$390.98M | -$372.18M | -$444.04M | -$395.89M | -5.1% |
| Net income to common | -$390.98M | -$372.18M | -$444.04M | -$395.89M | -5.1% |
| Basic EPS | -1.09 | -1.28 | -1.89 | -2.49 | +14.8% |
| Diluted EPS | -1.09 | -1.28 | -1.89 | -2.49 | +14.5% |
| EBIT | -$398.21M | -$395.28M | -$460.56M | -$398.88M | -0.7% |
| EBITDA | -$350.89M | -$347.21M | -$427.43M | -$377.74M | -1.1% |
| Basic shares | 357.35M | 289.88M | 235.13M | 159.26M | +23.3% |
| Diluted shares | 357.35M | 289.88M | 235.13M | 159.26M | +23.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $163.08M | $115.69M | $114.89M | $231.73M | — | +41.0% |
| Cash & short-term investments | $296.98M | $323.78M | $279.87M | $471.85M | — | -8.3% |
| Accounts receivable | $82.45M | $69.34M | $151.00K | $0 | — | +18.9% |
| Inventory | $51.68M | $51.52M | $10.37M | $0 | — | +0.3% |
| Total current assets | $442.69M | $457.02M | $307.85M | $479.12M | — | -3.1% |
| Property, plant & equipment | $177.01M | $164.28M | $176.54M | $178.25M | — | +7.7% |
| Goodwill & intangibles | $279.32M | $282.40M | $229.26M | $0 | — | -1.1% |
| Total assets | $913.17M | $910.43M | $780.35M | $663.98M | — | +0.3% |
| Total current liabilities | $138.36M | $122.34M | $110.31M | $91.48M | — | +13.1% |
| Current debt | $1.00M | — | — | — | — | — |
| Long-term debt | — | $1.00M | $1.00M | $1.00M | $1.00M | — |
| Total debt | $49.44M | $58.26M | $75.86M | $85.45M | — | -15.1% |
| Total liabilities | $214.59M | $200.02M | $195.74M | $164.34M | — | +7.3% |
| Retained earnings | -$2.78B | -$2.38B | -$2.01B | -$1.57B | — | -16.4% |
| Shareholder equity | $698.58M | $710.40M | $584.61M | $499.64M | — | -1.7% |
| Working capital | $304.33M | $334.68M | $197.54M | $387.63M | — | -9.1% |
| Net tangible assets | $419.26M | $428.01M | $355.36M | $499.64M | — | -2.0% |
| Shares issued | 411.94M | 305.25M | 256.14M | 187.81M | — | +35.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$390.98M | -$372.18M | -$444.04M | -$395.89M | -5.1% |
| Depreciation & amortisation | $47.32M | $48.07M | $33.13M | $21.14M | -1.6% |
| Stock-based compensation | $61.58M | $109.63M | $62.63M | $84.02M | -43.8% |
| Change in working capital | -$24.27M | -$127.02M | -$6.52M | -$2.89M | +80.9% |
| Operating cash flow | -$302.41M | -$352.98M | -$361.82M | -$292.76M | +14.3% |
| Capital expenditure | -$33.84M | -$11.07M | -$22.29M | -$20.43M | -205.7% |
| Investing cash flow | $47.50M | -$96.41M | -$155.24M | $256.45M | +149.3% |
| Financing cash flow | $300.77M | $390.66M | $462.96M | $190.15M | -23.0% |
| Free cash flow | -$336.24M | -$364.05M | -$384.11M | -$313.18M | +7.6% |
| End cash position | $169.06M | $122.05M | $181.32M | $238.16M | +38.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $99.31M | $71.43M | $86.77M | $67.45M | $59.95M | +39.0% |
| Operating revenue | $100.66M | $72.54M | $88.97M | $68.52M | $60.87M | +38.8% |
| Cost of revenue | $43.59M | $42.50M | $43.11M | $38.48M | $48.88M | +2.6% |
| Gross profit | $55.72M | $28.93M | $43.66M | $28.98M | $11.07M | +92.6% |
| Research & development | $58.85M | $62.49M | $71.20M | $75.17M | $77.93M | -5.8% |
| Selling, general & admin | $39.27M | $38.95M | $36.40M | $34.55M | $37.57M | +0.8% |
| Total operating expense | $107.62M | $109.97M | $117.12M | $118.74M | $124.84M | -2.1% |
| Operating income | -$51.91M | -$81.04M | -$73.46M | -$89.76M | -$113.77M | +36.0% |
| Net interest income | $3.22M | $1.33M | $1.74M | $1.24M | $4.10M | +141.3% |
| Pre-tax income | -$48.69M | -$79.71M | -$71.72M | -$93.66M | -$109.67M | +38.9% |
| Tax provision | -$1.37M | -$665.00K | $184.00K | -$2.40M | $1.99M | -106.5% |
| Net income | -$47.31M | -$79.05M | -$71.90M | -$91.25M | -$111.66M | +40.1% |
| Net income to common | -$47.31M | -$79.05M | -$71.90M | -$91.25M | -$111.66M | +40.1% |
| Basic EPS | -0.11 | -0.19 | -0.18 | -0.25 | -0.33 | +42.1% |
| Diluted EPS | -0.11 | -0.19 | -0.18 | -0.25 | -0.33 | +42.1% |
| EBIT | -$51.91M | -$81.04M | -$73.46M | -$89.76M | -$113.77M | +36.0% |
| EBITDA | -$41.50M | -$70.63M | -$60.82M | -$78.24M | -$101.55M | +41.2% |
| Basic shares | 450.19M | 418.51M | 406.97M | 364.04M | 334.51M | +7.6% |
| Diluted shares | 450.19M | 418.51M | 406.97M | 364.04M | 334.51M | +7.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $110.77M | $196.51M | $163.08M | $158.13M | $132.47M | — | -43.6% |
| Cash & short-term investments | $110.77M | $313.44M | $296.98M | $300.80M | $301.18M | — | -64.7% |
| Accounts receivable | $102.12M | $81.76M | $82.45M | $66.76M | $59.94M | — | +24.9% |
| Inventory | $55.59M | $58.38M | $51.68M | $51.71M | $49.83M | — | -4.8% |
| Total current assets | $464.26M | $466.50M | $442.69M | $429.09M | $422.50M | — | -0.5% |
| Property, plant & equipment | — | $175.78M | $177.01M | $175.41M | $172.42M | $162.49M | — |
| Goodwill & intangibles | $263.89M | $269.10M | $279.32M | $285.21M | $296.25M | — | -1.9% |
| Total assets | $915.53M | $925.66M | $913.17M | $904.95M | $907.44M | — | -1.1% |
| Total current liabilities | $106.85M | $129.42M | $138.36M | $125.78M | $129.16M | — | -17.4% |
| Current debt | — | $1.00M | $1.00M | $1.00M | $1.00M | $1.00M | — |
| Total debt | $46.00M | $47.78M | $49.44M | $52.49M | $53.17M | — | -3.7% |
| Total liabilities | $179.49M | $203.91M | $214.59M | $202.66M | $208.95M | — | -12.0% |
| Retained earnings | -$2.90B | -$2.85B | -$2.78B | -$2.70B | -$2.61B | — | -1.7% |
| Shareholder equity | $722.95M | $721.75M | $698.58M | $702.29M | $698.49M | — | +0.2% |
| Working capital | $357.41M | $337.08M | $304.33M | $303.31M | $293.35M | — | +6.0% |
| Net tangible assets | $459.05M | $452.65M | $419.26M | $417.08M | $402.24M | — | +1.4% |
| Shares issued | 452.97M | 438.11M | 411.94M | 385.46M | 333.93M | — | +3.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$47.31M | -$79.05M | -$71.90M | -$91.25M | -$111.66M | +40.1% |
| Depreciation & amortisation | $10.40M | $10.41M | $12.64M | $11.52M | $12.23M | -0.1% |
| Stock-based compensation | $11.73M | $11.27M | $11.82M | $11.90M | $14.94M | +4.1% |
| Change in working capital | -$35.83M | -$12.88M | -$7.29M | -$8.37M | $8.89M | -178.1% |
| Operating cash flow | -$60.84M | -$72.07M | -$52.56M | -$78.70M | -$67.45M | +15.6% |
| Capital expenditure | -$5.44M | -$6.61M | -$9.32M | -$10.84M | -$7.46M | +17.7% |
| Investing cash flow | -$74.05M | $11.39M | $775.00K | $17.01M | $13.84M | -749.9% |
| Financing cash flow | $49.29M | $94.33M | $56.17M | $88.06M | $13.23M | -47.8% |
| Free cash flow | -$66.28M | -$78.68M | -$61.88M | -$89.55M | -$74.91M | +15.8% |
| End cash position | $116.77M | $202.50M | $169.06M | $164.10M | $138.41M | -42.3% |
Options analytics
Put / call volume
2.71
Put-heavy session
Put / call open interest
0.46
Positioning, not flow
Max pain
13.00
+0.3% from spot
ATM implied vol
84.0%
Nearest strike to spot
Skew (10% OTM)
+12.1%
Puts bid over calls
Call volume
1.84K
Contracts, this expiry
Put volume
4.98K
Contracts, this expiry
Heaviest call OI
15.00
936 contracts
Heaviest put OI
13.50
522 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.13 | -0.11 | +18.4% |
| Mar 2026 | -0.15 | -0.19 | -23.8% |
| Dec 2025 | -0.18 | -0.18 | -2.0% |
| Sep 2025 | -0.26 | -0.25 | +2.8% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.09 | 8 | $113.19M | +67.8% |
| Next quarter | -0.08 | 8 | $124.33M | +43.3% |
| Current year | -0.46 | 8 | $408.24M | +54.9% |
| Next year | -0.24 | 8 | $575.24M | +40.9% |
Analyst targets & ownership
Mean target$12.80
High target$20.00
Low target$6.00
Implied upside-1.31%
Analyst count10
ConsensusBUY
Strong buy / Buy2 / 6
Hold2
Sell / Strong sell0 / 0
Held by insiders0.35%
Held by institutions70.70%
Institutions holding384
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
12.78
+1.48% from price
SMA 20
11.13
+16.46% from price
SMA 50
8.62
+50.42% from price
SMA 100
6.41
+102.33% from price
SMA 200
4.84
+167.56% from price
EMA 12
12.59
+3.04% from price
EMA 26
11.00
+17.86% from price
EMA 50
9.29
+39.63% from price
RSI (14)
65.7
Neutral
MACD (12,26,9)
1.58
Hist 0.20
ATR (14)
1.02
7.84% of price
Realised vol 30D
94.9%
Annualised
Bollinger upper
15.40
20, 2σ
Bollinger lower
6.86
20, 2σ
50 / 200 cross
Golden
8.62 vs 4.84
Trend bias
Above 200
+167.56%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.19
More volatile than market
Correlation to SPY
0.15
Largely independent
Realised vol 30D
94.9%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-39.0%
Peak to trough
Max drawdown 5Y
-94.0%
Peak to trough
ATR 14
1.02
7.84% of price
Beta (reported)
0.76
5Y monthly, from filing
Short interest
Shares short
87.13M
Prior 102.94M
Change vs prior
-15.4%
Shorts covering
% of float
20.57%
Heavily shorted
% of shares out
19.23%
Against total outstanding
Days to cover
6.0
Crowded exit
Float
394.31M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 30, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Sep 29, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 17, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Aug 25, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| Aug 20, 26 | UBS | MAINTAINED | Neutral | Neutral |
| Aug 18, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
| Aug 7, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Aug 7, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| May 8, 26 | Chardan Capital | MAINTAINED | Buy | Buy |
| Apr 10, 26 | Chardan Capital | MAINTAINED | Buy | Buy |
| Mar 5, 26 | UBS | MAINTAINED | Neutral | Neutral |
| Mar 3, 26 | Citizens | UPGRADE | Market Perform | Market Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:100
Split dateSep 26, 2013
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-10-05
Corporate Changes & Voting Matters
8-K · 2026-09-29
Corporate Changes & Voting Matters
8-K · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-07-02
Offering Registrations
S-8 · 2026-06-18
Corporate Changes & Voting Matters
8-K · 2026-06-10
Periodic Financial Reports
10-Q · 2026-05-07
Annual Report to Shareholders
ARS · 2026-05-01
Headlines
Why Iovance Biotherapeutics (IOVA) Effortlessly Soared 256% in Q3
Insider Monkey · 3d ago
Iovance Biotherapeutics (IOVA) Stock Gets Fair Value Boost On Amtagvi Demand And Margin Outlook
Simply Wall St. · 3d ago
Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
GlobeNewswire · 6d ago
IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026
Zacks · 7d ago
Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains?
Zacks · 7d ago
Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump?
Stocktwits · 7d ago
Why Did IOVA, ABCL, CRWD Stocks Surge To 52-Week Highs Today?
Stocktwits · 7d ago
Iovance Biotherapeutics (IOVA) Eyes 60% Revenue Growth, Shares Jump 31%
Insider Monkey · 7d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.